We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-10.95%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.5B
AUM Growth
-$293M
Cap. Flow
-$295M
Cap. Flow %
-11.83%
Top 10 Hldgs %
36.69%
Holding
119
New
16
Increased
26
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$120M
2
VTRS icon
Viatris
VTRS
+$32.1M
3
VCEL icon
Vericel Corp
VCEL
+$31.5M
4
AGN
Allergan plc
AGN
+$29.5M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$28.9M

Top Sells

Rank Stock Value
1
DBVT
DBV Technologies
DBVT
+$65.1M
2
ECYT
Endocyte, Inc. Common Stock
ECYT
+$62.4M
3
ACHC icon
Acadia Healthcare
ACHC
+$27.8M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$26.9M
5
RGNX icon
Regenxbio
RGNX
+$20.8M

Sector Composition

Rank Sector Weight
1 Healthcare 69.79%
2 Financials 1.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
51
DELISTED
Cymabay Therapeutics
CBAY
$10.6M 0.42%
1,343,181
– –
BOLD
52
DELISTED
Audentes Therapeutics, Inc
BOLD
$10.5M 0.42%
493,901
– –
SIOX
53
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$9.96M 0.4%
+1,250,000
New +$18M
CTMX icon
54
CytomX Therapeutics
CTMX
$788M
$9.4M 0.38%
622,548
-107,400
-15% -$1.59M
RVLP
55
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$8.82M 0.35%
+1,138,256
New +$9.11M
ALLO icon
56
Allogene Therapeutics
ALLO
$618M
$8.8M 0.35%
+326,797
New +$8.68M
EXAS
57
DELISTED
Exact Sciences
EXAS
$8.14M 0.33%
+129,000
New +$8.85M
RYTM icon
58
Rhythm Pharmaceuticals
RYTM
$7.31B
$7.82M 0.31%
291,005
-74,684
-20% -$2.06M
SYBX
59
DELISTED
Synlogic
SYBX
$7.76M 0.31%
73,843
-17,167
-19% -$2.26M
ATNX
60
DELISTED
Athenex, Inc. Common Stock
ATNX
$7.75M 0.31%
+30,535
New +$7.77M
AUTL
61
Autolus Therapeutics
AUTL
$383M
$7.74M 0.31%
235,576
-14,424
-6% -$475K
NVTA
62
DELISTED
Invitae Corporation
NVTA
$7.61M 0.3%
688,062
– –
SYRS
63
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.07M 0.28%
126,895
– –
AVDL
64
DELISTED
Avadel Pharmaceuticals
AVDL
$7.02M 0.28%
2,722,241
– –
LIVN icon
65
LivaNova
LIVN
$4.43B
$6.54M 0.26%
71,500
– –
ARDX icon
66
Ardelyx
ARDX
$1.28B
$5.3M 0.21%
2,962,922
-529,000
-15% -$1.56M
KPTI icon
67
Karyopharm Therapeutics
KPTI
$216M
$4.45M 0.18%
31,667
– –
ALIM
68
DELISTED
Alimera Sciences
ALIM
$4.35M 0.17%
403,529
– –
RCKT icon
69
Rocket Pharmaceuticals
RCKT
$376M
$4.15M 0.17%
280,000
– –
PFNX
70
DELISTED
Pfenex Inc.
PFNX
$3.41M 0.14%
1,069,514
– –
STIM icon
71
Neuronetics
STIM
$113M
$3.08M 0.12%
+159,000
New +$3.49M
TARA icon
72
Protara Therapeutics
TARA
$230M
$2.78M 0.11%
30,622
– –
OPCH icon
73
Option Care Health
OPCH
$3.41B
$2.74M 0.11%
191,750
-64,095
-25% -$845K
AAC
74
DELISTED
AAC Holdings
AAC
$2.71M 0.11%
1,936,027
+82,029
+4% +$329K
CNST
75
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$2.55M 0.1%
635,843
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2018 Portfolio in Review

As of Q4 2018, Deerfield Management held 119 positions worth $2.5B, down 11% from $2.79B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Deerfield Management withdrew a net $295M in Q4 2018, closing 21 positions and reducing 20 holdings. Its most notable exit was DBV Technologies, an estimated $65.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 69% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Orchard Therapeutics plc American Depositary Shares worth $126M.

  • Deerfield Management's largest Q4 2018 buy was Orchard Therapeutics plc American Depositary Shares: 802,360 shares worth $126M.
  • Deerfield Management added most to Viatris in Q4 2018, an estimated $32.1M increase.
  • Deerfield Management's biggest Q4 2018 reduction was Acadia Healthcare, cutting an estimated $27.8M.
  • Deerfield Management fully exited DBV Technologies in Q4 2018, selling an estimated $65.1M.
  • Deerfield Management's ten largest holdings make up 37% of its $2.5B portfolio in Q4 2018.
  • Deerfield Management opened 16 new positions and closed 21 in Q4 2018.
  • Deerfield Management's portfolio value fell 11% quarter-over-quarter to $2.5B.

Based on Deerfield Management's 13F filing for Q4 2018, filed 14 Feb 2019.